PEG-MGF

PEG-MGF is the polyethylene glycol (PEG)-conjugated form of Mechano Growth Factor, the 24-amino-acid C-terminal E-peptide domain derived from the IGF-1Ec splice variant (sequence: YQPPSTNKNTKSQRRKGSTFEEHK). MGF is naturally produced in skeletal muscle in response to mechanical stress — resistance exercise, stretch, or injury — and acts as a local paracrine signal that specifically activates quiescent satellite cells (muscle stem cells), driving them from G0 into the proliferative phase of the cell cycle to expand the precursor pool available for muscle repair and growth.

The mechanism is fundamentally distinct from mature IGF-1 signaling: while both are produced from the same IGF-1 gene through alternative splicing, MGF's unique C-terminal E-domain targets satellite cell activation through MAPK/ERK-mediated proliferation signaling, whereas mature IGF-1 (which lacks the E-domain) primarily promotes myoblast differentiation and protein synthesis via PI3K/Akt/mTOR. This temporal separation reflects the natural muscle-repair sequence: MGF is expressed first (within hours of damage), activating and expanding satellite cells; IGF-1 follows (peaking 24–48 hours later), driving differentiation and hypertrophy of the expanded precursor population. Administering MGF independently of this sequence selectively engages the early proliferative phase.

The PEGylation is the critical enabling technology: native MGF has a half-life of only 5–7 minutes due to rapid proteolytic degradation, making it practically unusable as a research tool. Conjugation with polyethylene glycol chains creates a hydrophilic "shield" that sterically hinders proteolytic enzymes from accessing the peptide backbone, extending the half-life to approximately 4–6 hours. This PEGylation also shifts MGF from a local paracrine factor to one that can distribute systemically after subcutaneous injection, reaching satellite cells in multiple muscle groups — a pharmacological difference from endogenous MGF that is both a practical advantage (convenience of systemic administration) and a research variable to account for (satellite cell activation in non-target tissues).

MGF was discovered in the late 1990s by Geoffrey Goldspink's group at the Royal Free Hospital (London), who identified that mechanical stretch of skeletal muscle induced expression of a distinct IGF-1 mRNA splice variant with a unique C-terminal E-domain. The term "Mechano Growth Factor" was coined to reflect its production specifically in response to mechanical stimuli — a discovery that linked mechanical loading directly to a specific molecular signal for muscle adaptation.

A landmark 2011 human cell study demonstrated that MGF E-peptide significantly increased satellite cell proliferation at concentrations as low as 3 ng/ml in muscle progenitor cells from young donors, and extended proliferative lifespan before senescence. However, receptor identification has been challenging: while MGF's effects are well-documented, the specific receptor mediating E-domain signaling has not been definitively characterized at the molecular level — a gap in the literature that distinguishes MGF research from the well-mapped IGF-1R/IR signaling paradigm. PEG-MGF emerged as a practical solution to native MGF's ultra-short half-life, enabling systematic research that would be impossible with the unmodified peptide. No human clinical trials have been conducted, and PEG-MGF is not FDA-approved.

Store lyophilized PEG-MGF at -20°C in a light-protected, desiccated container. The PEG moiety provides some protection against degradation, but the underlying 24-amino-acid peptide remains susceptible to hydrolysis and oxidation. Minimize vial-open time in humid environments. Stability under optimal conditions is expected to exceed 18 months, though long-term PEG-conjugated peptide stability data is less extensive than for non-pegylated peptides.

After reconstitution with bacteriostatic water, PEG-MGF should be refrigerated at 2–8°C and used within 21 days. The PEG moiety increases solubility and reduces surface adsorption compared to non-pegylated peptides. The solution should be clear and slightly more viscous than non-pegylated peptide solutions due to the PEG component — this is normal and expected. Do not freeze reconstituted PEG-MGF; freezing can cause PEG-chain precipitation and phase separation. Protect from light.